1 source 2h ago
Anthropic Acquires Mithril Medicine To Begin In-House Drug Discovery
Anthropic announced it has acquired Mithril Medicine, a company developing two muscular dystrophy treatments, and started its own drug discovery work.
Reporting from 1 source: GIGAZINE.
Why it matters
Anthropic is now running drug discovery rather than only supplying a model to partners, and a candidate from its acquired work could reach human clinical trials as early as late 2028.
Key Facts
- Anthropic acquired Mithril Medicine, a company developing two types of muscular dystrophy treatments.
- Mithril founder and sole employee Cody Traumberger used Claude to coordinate joint experiments with 11 external laboratories.
- Traumberger advanced a muscular dystrophy candidate treatment from the idea stage to promising mouse experiment results in 18 months.
- Anthropic holds research partnerships with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group.
- A muscular dystrophy drug candidate at a level suitable for human clinical trials could be ready as early as late 2028.
Mithril's founder and sole employee, Cody Traumberger, used Claude for contracting, procurement and coordination of joint experiments with 11 external laboratories, advancing a candidate treatment from idea to promising mouse results in 18 months. Anthropic also cited research partnerships with six organizations.
Anthropic lists three returns from the effort: a clearer map of where Claude helps and where it fails across drug discovery tasks, a case study for the wider life sciences field, and the prospect of new drugs for food allergies, rare pediatric diseases and multiple cancers.
In work with Generate Biomedicines on CAR-T cell therapy, a new design was proposed to extend the therapy from blood cancers to solid cancers, and testing confirmed one design was 70 percent more compact than conventional designs with higher efficacy. Traumberger will stay at Anthropic and continue the muscular dystrophy research alongside new work.
Written with AI by Yomimono from the 1 cited source below, including Japanese-language reporting where cited. See our editorial policy.
Add Yomimono as a preferred source on Google